• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[三种预后评分系统对评估慢性髓性白血病患者预后的疗效]

[Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].

作者信息

Huang Jing, Zhao Xielan

机构信息

Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Aug;41(8):809-14. doi: 10.11817/j.issn.1672-7347.2016.08.006.

DOI:10.11817/j.issn.1672-7347.2016.08.006
PMID:27600007
Abstract

OBJECTIVE

To retrospectively analyze the efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia (CML) in chronic phase (CP).

METHODS

In this retrospective cohort study, we collected 234 patients with CML in CP, who were treated with imatinib mesylate (IM). Patients were stratified into low-, intermediate- and high- risk groups according to three scoring systems (Sokal, Hasford and EUTOS), respectively. We compared the agreement of overall survival (OS), progression free survival (PFS), event free survival (EFS) in CML patients stratified by three prognostic scoring systems. The median for follow-up was 20.5 months.

RESULTS

EUTOS scoring system: In the low- and high-risk groups, the 5-year OS was 94.6% and 84.7% (P=0.011), 5-year EFS was 92.6% and 77.6% (P=0.001), and 5-year PFS was 95.3% and 82.4% (P=0.001), respectively. While stratified by Sokal or Hasford scoring system, there was no significant the correlation between low-, intermediate- and high- risk groups with the prognosis for CML patients (P>0.05). Compared with Sokal and Hasford scoring system, the outcome of EUTOS prognostic scoring system showed highly accordance with 5-year expect OS, PFS and EFS of CML patients.

CONCLUSION

EUTOS scoring system could predict the long-time outcome of CML-CP patients better than Sokal and Hasford scoring system. Chang of treatment may affect the prognostic value of EUTOS scoring system.

摘要

目的

回顾性分析三种预后评分系统对慢性粒细胞白血病(CML)慢性期(CP)患者预后评估的疗效。

方法

在这项回顾性队列研究中,我们收集了234例接受甲磺酸伊马替尼(IM)治疗的CP期CML患者。根据三种评分系统(Sokal、Hasford和EUTOS)分别将患者分为低、中、高风险组。我们比较了三种预后评分系统分层的CML患者总生存期(OS)、无进展生存期(PFS)、无事件生存期(EFS)的一致性。随访时间中位数为20.5个月。

结果

EUTOS评分系统:在低风险和高风险组中,5年总生存率分别为94.6%和84.7%(P = 0.011),5年无事件生存率分别为92.6%和77.6%(P = 0.001),5年无进展生存率分别为95.3%和82.4%(P = 0.001)。而按Sokal或Hasford评分系统分层时,低、中、高风险组与CML患者预后之间无显著相关性(P>0.05)。与Sokal和Hasford评分系统相比,EUTOS预后评分系统的结果与CML患者5年预期总生存率、无进展生存率和无事件生存率高度一致。

结论

EUTOS评分系统比Sokal和Hasford评分系统能更好地预测CML-CP患者的长期预后。治疗的改变可能会影响EUTOS评分系统的预后价值。

相似文献

1
[Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].[三种预后评分系统对评估慢性髓性白血病患者预后的疗效]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Aug;41(8):809-14. doi: 10.11817/j.issn.1672-7347.2016.08.006.
2
EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.在接受一线甲磺酸伊马替尼治疗的慢性粒细胞白血病(CML)患者中,EUTOS CML预后评分系统比欧洲/哈斯福德(Euro/Hasford)和索卡尔(Sokal)系统能更好地预测基于欧洲白血病网络(ELN)的“无事件生存期”。
Hematology. 2013 Sep;18(5):247-52. doi: 10.1179/1607845412Y.0000000071. Epub 2013 Mar 20.
3
[Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].[Sokal、Hasford和EUTOS预后评分系统在慢性髓性白血病中的临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2014 Aug;35(8):743-6. doi: 10.3760/cma.j.issn.0253-2727.2014.08.017.
4
Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.改变治疗方式可能会影响欧洲治疗结果研究评分对慢性髓性白血病患者预后的预测能力。
Turk J Haematol. 2017 Mar 1;34(1):10-15. doi: 10.4274/tjh.2016.0156. Epub 2016 Oct 18.
5
Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.诊断时的中度贫血是慢性期慢性髓性白血病患者一线使用伊马替尼时EUTOS、Sokal和Hasford生存及治疗反应评分的独立预后标志物。
Curr Med Res Opin. 2017 Oct;33(10):1737-1744. doi: 10.1080/03007995.2017.1356708. Epub 2017 Aug 11.
6
Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.比较 Sokal、Hasford 和 EUTOS 评分在接受伊马替尼治疗的中国慢性期慢性髓性白血病患者人群中的实用性和适用性。
Onco Targets Ther. 2015 Sep 7;8:2485-92. doi: 10.2147/OTT.S85313. eCollection 2015.
7
Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?在伊马替尼时代,使用骨髓参数能否提高慢性髓性白血病风险预测评分的效能?
Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):375-381. doi: 10.1016/j.clml.2017.02.029. Epub 2017 Mar 30.
8
Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).突尼斯慢性髓性白血病患者:伊马替尼时代的流行病学与预后(一项多中心研究经验)
Ann Hematol. 2018 Apr;97(4):597-604. doi: 10.1007/s00277-017-3224-2. Epub 2018 Jan 6.
9
Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.三种预后评分系统对儿童慢性粒细胞白血病慢性期一线伊马替尼治疗反应和结局的预测效能
Indian J Med Paediatr Oncol. 2017 Jul-Sep;38(3):282-286. doi: 10.4103/ijmpo.ijmpo_104_16.
10
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.EUTOS 长期生存评分可预测基于实践队列的慢性髓系白血病患者的疾病特异性死亡率和分子反应。
Cancer Med. 2020 Dec;9(23):8931-8939. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.